<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Class III beta-tubulin (TUBB3) expression in <z:mp ids='MP_0002038'>carcinoma</z:mp> is associated with resistance to tubulin-binding chemotherapeutic agents </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, follicular dendritic cells (<z:chebi fb="17" ids="38848">FDCs</z:chebi>) were reported to express TUBB3 under physiologic conditions </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated TUBB3 expression in a wide range of <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> using immunohistochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>Dual immunostaining for Bcl-6 and TUBB3 revealed that some germinal center B cells also express TUBB3 in addition to <z:chebi fb="17" ids="38848">FDCs</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>In Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HLs</z:e>), 47.1% (40/85) expressed TUBB3 in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells with an <z:hpo ids='HP_0000001'>all</z:hpo>-or-none pattern </plain></SENT>
<SENT sid="5" pm="."><plain>TUBB3 expression in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> was more common in mixed cellularity type than nodular <z:mp ids='MP_0000612'>sclerosis</z:mp> type (P=0.032) </plain></SENT>
<SENT sid="6" pm="."><plain>Among non-<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HLs</z:e>, 79.3% (23/29) of anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e>), 8% (2/25) of extranodal natural killer/T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and 75% (21/28) of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> showed TUBB3 expression with an <z:hpo ids='HP_0000001'>all</z:hpo>-or-none pattern </plain></SENT>
<SENT sid="7" pm="."><plain>Of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 15.2% (32/210) expressed TUBB3 in a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> pattern </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e>, TUBB3 expression was more common in systemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e> than in primary cutaneous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e> (P=0.046) </plain></SENT>
<SENT sid="9" pm="."><plain>Diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with a germinal center B-like subgroup exhibited TUBB3 expression more frequently than non-GCB-like subgroup (P=0.01) </plain></SENT>
<SENT sid="10" pm="."><plain>Otherwise, none of the 18 angioimmunoblastic T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>; 18 peripheral T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, not otherwise specified; 12 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>; 62 marginal zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo>; 7 mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>; 8 small lymphocytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>; or 2 FDC <z:hpo ids='HP_0100242'>sarcomas</z:hpo> expressed TUBB3 </plain></SENT>
<SENT sid="11" pm="."><plain>In angioimmunoblastic T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="C0017531" disease_type="Disease or Syndrome" abbrv="GLNH|AFLH">Castleman disease</z:e>, TUBB3 was positive in immunoblasts corresponding to Epstein-Barr virus-infected or Kaposi <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:e sem="disease" ids="C0019340" disease_type="Disease or Syndrome" abbrv="">herpes</z:e> virus-infected cells </plain></SENT>
<SENT sid="12" pm="."><plain>A variety of neoplastic and non-neoplastic <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> exhibited characteristic TUBB3 expression patterns; these results suggest potential for diagnostic utility, some insight into the pathobiology of TUBB3 expression, and potential therapeutic implications </plain></SENT>
</text></document>